Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...